Estás usando un navegador no soportado
Usar Internet Explorer está desaconsejado por problemas de seguridad. Para ver correctamente esta web, por favor use cualquier navegador moderno: Chrome, Firefox, Edge, Safari u otro de su elección.
En este apartado encontrará una actualización mensual de Trastornos del Movimiento
FILTRAR POR:
Por tema
3520 ARTÍCULOS , VIENDO DEL 1801 AL 1815
[Braak's hypothesis and non-motor symptoms of Parkinson disease]
Saito Y, Murayama S.
Brain Nerve. 2012 Apr;64(4):444-52.
[Does early detection of non-motor symptoms facilitate early treatment of Parkinson's disease?]
Hasegawa K.
Brain Nerve. 2012 Apr;64(4):453-61.
Molecular insights into Parkinson's disease
Rochet JC, Hay BA, Guo M.
Prog Mol Biol Transl Sci. 2012;107:125-88. doi: 10.1016/B978-0-12-385883-2.00011-4.
Biology of mitochondria in neurodegenerative diseases
Martin LJ.
Prog Mol Biol Transl Sci. 2012;107:355-415. doi: 10.1016/B978-0-12-385883-2.00005-9.
Schapira AH.
Lancet. 2012 May 12;379(9828):1825-34. doi: 10.1016/S0140-6736(11)61305-6. Epub 2012 Apr 5.
Inhibitors of Catechol-O-Methyltransferase
Barrow JC.
CNS Neurol Disord Drug Targets. 2012 May;11(3):324-32. doi: 10.2174/187152712800672517.
Espinoza S, Manago F, Leo D, Sotnikova TD, Gainetdinov RR.
CNS Neurol Disord Drug Targets. 2012 May;11(3):251-63. doi: 10.2174/187152712800672436.
Catechol-o-methyltransferase and Alzheimer's disease: a review of biological and genetic findings
Serretti A, Olgiati P.
CNS Neurol Disord Drug Targets. 2012 May;11(3):299-305. doi: 10.2174/187152712800672472.
Redox sensitivity of tyrosine hydroxylase activity and expression in dopaminergic dysfunction
Di Giovanni G, Pessia M, Di Maio R.
CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):419-29. doi: 10.2174/187152712800792938.
Motor and non-motor features of Parkinson's disease - a review of clinical and experimental studies
Lima MM, Martins EF, Delattre AM, Proenca MB, Mori MA, Carabelli B, Ferraz AC.
CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):439-49. doi: 10.2174/187152712800792893.
Mitochondria as an easy target to oxidative stress events in Parkinson's disease
Reale M, Pesce M, Priyadarshini M, Kamal MA, Patruno A.
CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):430-8. doi: 10.2174/187152712800792875.
New agents promote neuroprotection in Parkinson's disease models
Santos CM.
CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):410-8. doi: 10.2174/187152712800792820.
Targeting Parkinson's - tyrosine hydroxylase and oxidative stress as points of interventions
Khan MS, Tabrez S, Priyadarshini M, Priyamvada S, Khan MM.
CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):369-80. doi: 10.2174/187152712800792848.
A synopsis on the role of tyrosine hydroxylase in Parkinson's disease
Tabrez S, Jabir NR, Shakil S, Greig NH, Alam Q, Abuzenadah AM, Damanhouri GA, Kamal MA.
CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):395-409. doi: 10.2174/187152712800792785.
The function of tyrosine hydroxylase in the normal and Parkinsonian brain
Tolleson C, Claassen D.
CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):381-6. doi: 10.2174/187152712800792794.
Actualización mensual Regístrese para recibir los avisos de actualización
Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.